Aktiv Pharma Group

Aktiv Pharma Group develops prefilled, ready-to-use pharmaceutical delivery systems built around the company’s glass-free, flexible container technology providing for unprecedented ruggedness, reliability, and ease of use.
ARAI is the next generation autoinjector platform for nerve agent antidotes and other medical countermeasures developed by Aktiv in close partnership with the US Government specifically for CBRNe defense applications. The platform supports high-volume injections, dual needle injections, and automated reconstitution of dry formulations. All ARAI configurations maintain operational consistency by sharing the same dimensions and user interface. The growing ARAI product pipeline currently includes: atropine, pralidoxime chloride, atropine and pralidoxime chloride dual injection, scopolamine, and tranexamic acid.